Connect Biopharma Holdings Ltd ADR CNTB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.36
- Day Range
- $1.34–1.39
- 52-Week Range
- $0.56–2.84
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $75.49 Mil
- Volume/Avg
- 58,379 / 171,079
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 81
- Website
- https://www.connectbiopharm.com
Valuation
|
Metric
|
CNTB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.93 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CNTB
|
|---|---|
Quick Ratio | 4.90 |
Current Ratio | 4.99 |
Interest Coverage | −2,698.87 |
Quick Ratio
CNTB
Profitability
|
Metric
|
CNTB
|
|---|---|
Return on Assets (Normalized) | −39.93% |
Return on Equity (Normalized) | −53.09% |
Return on Invested Capital (Normalized) | −47.69% |
Return on Assets
CNTB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Xbjhwwjtf | Xjsjt | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cswybsvjq | Qfnnrdv | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jhcpdpkm | Jzfbcn | $97.8 Bil | |
MRNA
| Moderna Inc | Zwhcvtr | Ldrc | $41.3 Bil | |
ARGX
| argenx SE ADR | Kjwxspbcr | Zzhx | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Gbcqbwhr | Jttmw | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mpykzmll | Qcpztp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vbfxptlfx | Nyndkw | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hjtktsgbnb | Vgjtp | $12.5 Bil | |
INCY
| Incyte Corp | Kdwkkks | Kltzp | $11.6 Bil |